首页> 外文OA文献 >The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

【2h】

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

机译：EGFR酪氨酸激酶抑制剂治疗EGFR突变型非小细胞肺癌患者的BIM缺失多态性及其临床意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lee Ji Yun; Ku Bo Mi; Lim Sung Hee; Lee Min-Young; Kim Haesu; Kim Moonjin; Kim Sungmin; Jung Hyun Ae; Sun Jong-Mu; Ahn Jin Seok; Park Keunchil; Ahn Myung-Ju;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors [J] . Lee Ji Yun, Ku Bo Mi, Lim Sung Hee, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第6期

机译：EGFR酪氨酸激酶抑制剂治疗EGFR突变型非小细胞肺癌患者的BIM缺失多态性及其临床意义
3. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors [J] . Kimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, Scientific reports. . 2019,第1期

机译：用EGFR-酪氨酸激酶抑制剂治疗EGFR-突变体非小细胞肺癌患者的表达及其临床意义
4. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors [J] . Zhang Xiaoqing, Fan Junwei, Li Yuping, Tumour biology : . 2016,第1期

机译：表皮生长因子受体（EGFR）和AKT1的多态性可作为EGFR酪氨酸激酶抑制剂治疗的晚期非小细胞肺癌患者临床结局的可能预测指标
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design [O] . Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, -1

机译：抗蛋白酶激酶抑制剂在EGFR-突变体肺癌患者中停止疾病眩光并对厄洛替尼或吉非替尼抗性的抗性 - 对临床试验设计的影响
8. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors [O] . Kimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, 2019

机译：用EGFR-酪氨酸激酶抑制剂治疗EGFR-突变体非小细胞肺癌患者的表达及其临床意义
9. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers. [R] . Engelman, J., Sequist, L. 2016

机译：缺乏BIm表达作为EGFR-突变和aLK阳性肺癌中靶向疗法的内在和获得性抗性的机制。

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

著录项

引文网络

相似文献

相关主题

期刊订阅